Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Frontiers in PharmacologyOpen Access

Dupilumab in patients with bullous pemphigoid and concomitant atopy

View Full Paper
Ask AI
Bookmark
Share

Authors

KJKaterina JobstSKStephan R. KünzelSBStefan Beissert

Discussion

Loading...

Member takes

Overview

Retrospective case series demonstrates dupilumab reduces bullous pemphigoid lesions in patients with atopic dermatitis, implying a safe, effective therapy.

Key Points

  • At week 12, all patients achieved complete remission of bullous skin lesions, highlighting dupilumab's effectiveness.
  • Clinical assessments showed significant pruritus improvement with 58.3% achieving complete resolution at week 12.
  • The investigation included twelve patients, average age 78.6, emphasizing the treatment's applicability in older adults.
  • Dupilumab was well tolerated with no adverse events reported, suggesting a strong safety profile in multimorbid patients.

Cite This Study

Jobst et al. (2025) studied this question.

synapsesocial.com/papers/68bb42212b87ece8dc958a79https://doi.org/10.3389/fphar.2025.1656089
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT2024 · 41 citations
  2. 2The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations2018 · 246 citations
  3. 3Rapid and sustained response to tralokinumab in a patient with severe bullous pemphigoid and end-stage kidney disease2023 · 13 citations
  4. 4Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update2023 · 58 citations
  5. 5IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker2022 · 17 citations